CompletedNot Applicable

Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus

Belarus86 participantsStarted 2013-07

Plain-language summary

The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing the degree of early allograft liver dysfunction, as assessed by postoperative levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), during first 7 postoperative days and by serum and histochemical markers of liver injury and inflammation.

Who can participate

Age range18 Years – 69 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Donor: age 15-65 years macrovesicular steatosis \< 40% (macroscopy or biopsy) sodium \<165 mmol/l ICU stay and ventilation \< 11 days cold ischemia time \< 13 hours AST \< 200 U/l ALT \< 200 U/l bilirubin \< 50 μmol/l application of norepinephrine is allowed * Recipient age: 18-69 Exclusion Criteria: Recipient: * live donor liver transplant * reduced and split grafts * multi organ failure

What they're measuring

Early Allograft Dysfunction

Timeframe: 1-7 postoperative days after liver transplant procedure

Trial details

NCT IDNCT01887171

SponsorRepublican Scientific and Practical Center for Organ and Tissue Transplantation

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-07

Results submitted2016-12-31

View on ClinicalTrials.gov More Early Allograft Dysfunction trials